1. To identify family members of people with type 1 diabetes that may be at risk for developing type 1 diabetes. 2. To monitor the metabolic and immunologic status of at-risk individuals. Eligible individuals will be offered enrollment in type 1 diabetes prevention studies. See website for more details https://www.trialnet.org/
The aim is to find out how overall health and wellness is related to need for pain medication after surgery.
To find out which of two commonly used IV fluids given in the Emergency Department for sepsis is most effective.
Our purpose is to look at the long-term neurodevelopmental outcomes of preterm neonatal brain abnormalities.
To explore the safety and treatment effect of intravenous (IV) Remodulin as add on therapy in neonates with PPHN compared to placebo.
This is a randomized, double-blind, placebo-controlled study that will evaluate the potential of tildacerfont to reduce GC burden in adult subjects with classic CAH who have LLD ≤ A4 ≤ 2.5x ULN and are on supraphysiologic doses of GC therapy (≥30 mg/day and ≤60 mg/day HCe). This will be the first study of tildacerfont to evaluate GC dose reduction. In addition, this study will characterize clinical outcomes after up to 76 weeks of treatment with tildacerfont. An optional Open-Label Extension Period will provide an open-label treatment with tildacerfont at 200 mg QD for up to 240 weeks.
Study early development in infants who have an older sibling with autism.
Understand the experiences of patients and parents in treatment decision making for children with Neuromuscular Scoliosis (NMS).
To better understand the effects of nutrition in early pregnancy on infant growth and development.
The objective of this study is to better understand the effects of chronic diseases, such as congenital heart disease, on blood vessel function and on blood characteristics.
